West Pharmaceutical Services, Inc. (NYSE:WST) Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its holdings in West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 25.1% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,400 shares of the medical instruments supplier’s stock after buying an additional 5,690 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in West Pharmaceutical Services were worth $11,238,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of West Pharmaceutical Services in the fourth quarter worth $300,250,000. Artisan Partners Limited Partnership lifted its holdings in West Pharmaceutical Services by 23.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,961,063 shares of the medical instruments supplier’s stock valued at $690,530,000 after purchasing an additional 369,792 shares in the last quarter. APG Asset Management US Inc. acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter worth about $88,227,000. TD Asset Management Inc boosted its stake in shares of West Pharmaceutical Services by 38.4% during the 4th quarter. TD Asset Management Inc now owns 659,560 shares of the medical instruments supplier’s stock worth $232,244,000 after purchasing an additional 183,153 shares during the last quarter. Finally, Findlay Park Partners LLP grew its holdings in shares of West Pharmaceutical Services by 65.2% during the fourth quarter. Findlay Park Partners LLP now owns 457,306 shares of the medical instruments supplier’s stock worth $161,027,000 after buying an additional 180,415 shares in the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $322.56 on Monday. The company has a market capitalization of $23.50 billion, a price-to-earnings ratio of 42.55, a PEG ratio of 5.70 and a beta of 1.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.95 and a current ratio of 2.61. West Pharmaceutical Services, Inc. has a 1 year low of $310.00 and a 1 year high of $415.73. The company’s 50 day simple moving average is $337.44 and its 200 day simple moving average is $359.40.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.27. The company had revenue of $695.40 million for the quarter, compared to analyst estimates of $670.62 million. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. The business’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.98 EPS. On average, sell-side analysts predict that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 7th. Shareholders of record on Wednesday, July 31st will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.25%. The ex-dividend date is Wednesday, July 31st. West Pharmaceutical Services’s dividend payout ratio (DPR) is 10.55%.

Insider Activity

In related news, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total value of $595,404.00. Following the sale, the senior vice president now directly owns 2,860 shares of the company’s stock, valued at $946,030.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Silji Abraham sold 1,800 shares of the company’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the completion of the sale, the senior vice president now directly owns 2,860 shares in the company, valued at approximately $946,030.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the completion of the transaction, the chief executive officer now owns 152,908 shares in the company, valued at approximately $56,063,718.20. The disclosure for this sale can be found here. Corporate insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Read More

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.